Sandhoff disease (SD) is caused by deficiency of N-acetyl-β-hexosaminidase (Hex) resulting in pathological accumulation of GM2 ganglioside in lysosomes of the central nervous system (CNS) and progressive neurodegeneration. Currently, there is no treatment for SD, which often results in death by the age of five years. Adeno-associated virus (AAV) gene therapy achieved global CNS Hex restoration and widespread normalization of storage in the SD mouse model. Using a similar treatment approach, we sought to translate the outcome in mice to the feline SD model as an important step toward human clinical trials. Sixteen weeks after four intracranial injections of AAVrh8 vectors, Hex activity was restored to above normal levels throughout the entire CNS and in cerebrospinal fluid, despite a humoral immune response to the vector. In accordance with significant normalization of a secondary lysosomal biomarker, ganglioside storage was substantially improved, but not completely cleared. At the study endpoint, 5-monthold AAV-treated SD cats had preserved neurological function and gait compared with untreated animals (humane endpoint, 4.4 ± 0.6 months) demonstrating clinical benefit from AAV treatment. Translation of widespread biochemical disease correction from the mouse to the feline SD model provides optimism for treatment of the larger human CNS with minimal modification of approach.
INTRODUCTION
The GM2 gangliosidoses are recessively inherited lysosomal storage diseases (LSDs) caused by impaired degradation of GM2 ganglioside (GM2) resulting in progressive neurodegeneration and early death. These disorders result from the deficiency of N-acetylβ-hexosaminidase (Hex; EC 3.2.1.52). Hex hydrolyzes terminal N-acetyl-galactosamine or N-acetyl-glucosamine residues from numerous glycoconjugates. The two major Hex isozymes, HexA (αβ) and HexB (ββ), have overlapping substrate specificities, but only HexA is capable of substantial GM2 catabolism in humans. Genetic deficiency of HEXA, encoding the Hex α-subunit, or HEXB, encoding the Hex β-subunit, causes Tay-Sachs disease and Sandhoff disease (SD), respectively. Tay-Sachs disease and SD are clinically similar, despite additional accumulation of neutral substrates in SD patients. 1 The GM2 gangliosidoses have a spectrum of clinical forms characterized by the age of disease onset and progression of clinical symptoms, which are largely determined by the residual level of HexA activity. 2 The infantile-onset form is most common, resulting from negligible HexA activity that leads to death by the age of 5 years. 1 There is currently no effective treatment for the GM2 gangliosidoses although several approaches have been tested without clinical success in human patients including substrate reduction therapy, [3] [4] [5] chemical chaperone therapy 6, 7 and bone marrow transplantation. 8 Hex deficiency affects the central nervous system (CNS) globally, so successful treatment strategies must target widespread areas of the brain and spinal cord. Adeno-associated virus (AAV) intracranial gene therapy has the potential to generate a permanent source of Hex in the CNS. The ability of vectortransduced cells to secrete a proportion of lysosomal enzyme and 'cross-correct' diseased cells, 9, 10 means that only a fraction of the brain would need to be transduced by AAV vectors. In addition to local diffusion, AAV vector and enzyme are distributed by axonal transport 11, 12 and cerebrospinal fluid (CSF) flow 11, 13 to regions widely dispersed from the injection site.
AAV gene therapy has proven effective in several animal models of LSDs, [13] [14] [15] [16] [17] including SD mice 18, 19 and SD cats. 20 Although mice are invaluable for the initial testing of therapies, cats have a brain size and complexity more analogous to humans and provide a better indication of the enzyme distribution challenges that must be overcome in humans. While the mouse brain is 1000 times smaller than that of a human infant, the cat brain is only 20 times smaller. Also, the typical mouse life span is 2 years whereas cats routinely live 12-15 years or longer. First described in 1977, feline SD provides an unparalleled opportunity to test gene therapy in a large animal model highly analogous to human infantile-onset SD in terms of enzymatic deficiency (0.00to 0.02-fold normal activity), neuropathology and clinical disease progression. [21] [22] [23] Up to a 2.3-fold mean increase in life span was previously reported for SD cats treated with bilateral thalamic 1 Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA; 2 injections of AAVrh8 vectors encoding feline Hex. Hex activity was restored to 0.83-to 5.5-fold that of normal levels throughout the cerebrum, but mean activity was substantially below normal in the cerebellum and was not evaluated in the spinal cord. 20 It is clear that gene therapy strategies for human clinical application will require more direct treatment of cerebellar pathology, which has been effectively addressed in the current study.
Studies in the related GM1 gangliosidosis feline model 24 and in SD mice 19 demonstrated that bilateral injection of AAV vectors in the forebrain and deep cerebellar nuclei is an effective method to globally restore CNS lysosomal enzyme activity resulting in the significant clearance of pathological storage material and increase in life span. The current study evaluated the extent of biochemical disease correction following thalamus and deep cerebellar nucleidirected gene therapy in the feline SD model.
RESULTS

Widespread enzyme and vector distribution
Three SD cats (11-762, 7-770 and 7-774) were injected bilaterally in the thalamus and deep cerebellar nuclei with monocistronic AAVrh8 vectors encoding feline Hex αand Hex β-subunits (1:1 ratio, 4.4 × 10 12 vector genomes total). As we reported previously, coexpression of α and β subunits is necessary for the formation of HexA, 20 the isozyme responsible for GM2 degradation in humans. Histochemical staining with a substrate cleaved specifically by Hex showed widespread Hex distribution in the brain of AAV-treated SD cats 16 weeks after injection (Figures 1a and b ). Hex staining was most intense at the parenchymal injection sites (blocks E and H in Figure 1b ). Spinal cord Hex distribution was also widespread and was most intense in the lumbar block O. In cat 7-770 (shown in Figure 1c ), Hex staining was highest in the dorsal funiculus, but also extended into the gray matter of all spinal cord blocks. In cats 11-762 and 7-774, Hex staining was not as well distributed in the gray matter of cervical spinal cord blocks I-K (Supplementary Figure S1 ). Hex activity in untreated SD cats was not detectable by staining with this naphthol-based histochemical substrate.
Hex activity was measured quantitatively with the synthetic fluorogenic substrates 4-methylumbelliferone-6-sulfa-2-acetamido-2-deoxy-β-D-glucopyranoside (MUGS) and 4-methylumbelliferone-N-acetyl-β-D-glucosaminide (MUG). MUGS binds to the same positively charged pocket in the α-subunit that binds GM2 ganglioside and is HexA-specific in humans and HexA-preferred in cats. MUG is hydrolyzed by the Hex αor β-active site and is a measure of total Hex activity. Residual Hex activity against MUGS in untreated SD cats was ⩽ 0.01-fold that of normal in the brain and ⩽ 0.02-fold that of normal in the spinal cord. In AAV-treated SD cats, mean Hex activity against MUGS was significantly higher than in untreated SD cats and normal cats (homozygous for the wild-type allele) in all brain (2.7-to 45-fold normal) and spinal cord (4.2-to 14-fold normal) blocks ( Table 1) . Results were similar with MUG substrate ( Supplementary Table S1 ). Ion exchange chromatography was used to calculate the relative production of each isozyme and demonstrated that the HexA:HexB ratio was comparable between AAV-treated SD cats and normal cats ( Figure 2 ).
Lysosomal enzyme gains access to and may be distributed via CSF and perivascular flow following intraparenchymal injection in mice 19 and cats. 24 Hex activity in CSF of AAV-treated SD cats ranged from 4.9-to 15-fold that of normal indicating that CSF transport may have been an effective mode of dissemination ( Supplementary Table S1 ). Additionally, enzyme was detected in pituitary tissue and sciatic nerve demonstrating transport to the neuroendocrine and peripheral nervous system following intraparenchymal injection (Table 1 and Supplementary Table S1 ). AAV vector was detected by quantitative PCR in all samples from AAV-treated SD cats indicating widespread vector dissemination from injection sites ( Supplementary Table S2 ). Humoral antibody response to the AAV vector A humoral antibody response to the AAV vector may result from vector entering the cervical lymph node via CSF transport or vector leakage into the vasculature as blood vessels are traversed during intraparenchymal injection. 25, 26 Serum antibody titers to the AAVrh8 capsid were undetectable in SD cats before treatment. Sixteen weeks after treatment, serum antibody titers were 1:65 536 in cats 7-774 and 7-770. Cat 11-762 had a lower antibody response, which peaked 6 weeks after injection at 1:4096 ( Figure 3 ). Histological analysis showed no evidence of a cellmediated response to the vector. The only abnormalities detected were (i) rare multifocal expansion of leptomeninges by accumulation of lymphocytes and fibroblasts, and (ii) scattered, moderately swollen cerebral cortical neurons and Purkinje cells, which both contained copious amounts of foamy, cytoplasmic storage vacuoles (Supplementary Figure S2 ). Both abnormalities were more diffusely present in untreated SD cats and are likely disease related.
Substantial normalization of storage material Total ganglioside sialic acid accumulates to several fold that of normal in the brain of SD cats, and GM2 accounts for 67% of total gangliosides compared with undetectable levels in normal cats. Asialo GM2 (GA2) is also elevated in the SD cat brain, but is undetectable in normal cats. 21, 27 Samples from cortex (block C), thalamus (block D), cerebellum (block G) and cervical intumescence of the spinal cord (CI, block K in Figure 1a ) were analyzed for ganglioside storage by high performance thin layer chromatography (HPTLC). Representative HPTLC plates in Figure 4 show that GM2 ganglioside clearance was virtually complete in the thalamus of treated cats (panel c). All samples of cerebral cortex ( Figure 4b ) and cerebellum ( Figure 4d ) showed decreases in GM2 storage, and clearance was complete in two of three cats. Similarly, GM2 in the CI was reduced after treatment, though substantial storage remained in the majority of cats ( Figure 4e ). All HPTLC plates were objectively quantified to calculate the cumulative effect of AAV therapy, and results are shown in Figure 5 . In untreated SD cats, Hex activity was negligible, and The activity of each isozyme was calculated by summing activities from fractions 1 to 8 (HexB) or 10 to 20 (HexA), and ratios of A:B were calculated. The inset table shows the A:B ratio for AAV-treated SD cats (n = 3, black squares), normal cats (n = 4, gray circles) and untreated SD cats (n = 1, gray triangles), and the graph shows a representative AAV-treated SD cat (7-770) along with a representative normal cat and untreated SD cat. The A:B ratio was not significantly different between AAV-treated SD cats and normal cats (P = 0.14). Hex activity was not detected in untreated SD cats. Peak heights depict enzyme activity, not specific activity, and therefore can only be used to compare relative isozyme levels (not absolute levels) between cats. Abbreviations: DEAE, diethylaminoethyl.
total sialic acid accumulated significantly to 1.9-to 4.0-fold that of normal (Figures 5a and b ). In AAV-treated SD cats, mean sialic acid storage was decreased in all samples, but remained significantly higher than that of normal in cortex C, thalamus and CI (Figure 5b ). GM2 and GA2 storage were absent in samples from normal cats with the exception of sample K in which trace amounts were detected. In untreated SD cats, GM2 and GA2 storage were significantly higher than in normal cats (Figures 5c  and d) . In AAV-treated SD cats, there was a significant reduction of GM2 and GA2 storage in the brain (GM2, 89-99%; GA2, 91-100%) and CI (GM2, 72%; GA2, 73%), although mean storage of GA2 and/ or GM2 remained significantly higher than that of normal in cortex C, cerebellum G and CI (Figures 5c and d) . Ganglioside storage was also analyzed in frontal cortex (block B), striatum (block C), rostral cerebellum (block F) and lumbar intumescence (LI, block O in Figure 1a ). Total sialic acid, GM2 and GA2 storage were substantially normalized in all AAV-treated versus untreated SD cats, but significance could not be determined for all samples because of low control numbers (normal, n = 2; untreated SD, n = 2 to 4) (Supplementary Figure S3 and Supplementary Table S3 ).
Partial normalization of a secondary lysosomal biomarker
In lysosomal storage diseases, activity of non-mutant lysosomal hydrolases is often elevated. 24, 28 In untreated SD cats, α-mannosidase activity was significantly elevated up to 8.4-fold that of normal in the brain and 11-fold that of normal in the spinal cord. Sixteen weeks after intraparenchymal injections of AAV-fHEXA and AAV-fHEXB, α-mannosidase activity was significantly reduced in all CNS blocks versus untreated SD cats. However, α-mannosidase activity remained significantly higher than in normal cats in most spinal cord blocks, revealing incomplete spinal cord restoration of this secondary lysosomal biomarker despite restoration of Hex activity to several fold that of normal. Lysosomal α-mannosidase activity was not normalized in pituitary, which had only a small increase in Hex activity ( Figure 6 and Table 1 ).
Delayed clinical disease progression
Disease onset in AAV-treated SD cats was delayed up to the 16 week post-treatment experimental endpoint versus untreated SD cats whose stereotypical disease progression began at the age of 1.3 ± 0.2 months with fine tremors of the head and tail. Clinical symptoms in untreated animals progressed according to the clinical rating scale in Figure 7a , which reflects an animal's departure from normal function. Cats reached the inability to stand on two consecutive days at the age of 4.4±0.6 months, which defined the humane endpoint. (Supplementary Video S1 shows an untreated SD cat at 3.2 months of age). When scored on the same clinical rating scale, the composite score of AAV-treated SD cats was 7.7 at the pre-determined study endpoint of the age of~5 months. In contrast, untreated SD cats reached a score of 3 (humane endpoint) by the age of 4.4 months (Figure 7b ). AAVtreated SD cats developed generalized hind limb muscle weakness at the same age as untreated SD cats (~2 months old), but subsequently, disease progression in treated cats was stabilized. At the study endpoint, cat 11-762 had a wide based stance (Supplementary Video S2) and cats 7-770 and 7-774 displayed mild ataxia. Although subtle tremors were present in all three AAV-treated SD cats, none developed overt whole-body tremors, which are evident in untreated SD cats by the age of 2.4 months and become progressively debilitating.
DISCUSSION
The GM2 gangliosidoses belong to a group of over 40 LSDs with a combined incidence of 1 in 7700 live births. 29 There is currently no effective treatment for human GM2 gangliosidoses, with palliative measures being the current standard of care. Enzyme replacement therapy, 30, 31 substrate reduction therapy [32] [33] [34] and stem cell transplantation [33] [34] [35] [36] have shown moderate success in mouse models of gangliosidoses, but similar efficacy in larger animals has not been achieved. 37, 38 Dramatic therapeutic effect using AAVmediated gene therapy was reported in the mouse model of SD, 18, 19 prompting our evaluation of this approach in SD cats as an intermediate step toward human application. Initial studies to test AAV gene therapy in the feline SD model utilized bilateral thalamic injections of AAV vectors and resulted in the first report of unequivocal therapeutic effect in a non-rodent gangliosidosis model. 20 Although the initial study was encouraging, Hex activity in the cerebellum of treated cats was far below normal and we did not believe that a thalamus-only approach was effective enough to pursue human clinical application. Superior CNS enzyme distribution and clinical therapeutic benefit was since demonstrated in GM1 gangliosidosis cats by delivering thalamus and deep cerebellar nuclei injections of AAV vectors. 24 In the current study, the thalamus and deep cerebellar nuclei treatment approach was tested in SD cats and resulted in near-global restoration of Hex activity to above-normal levels throughout the CNS, with accompanying decreases in storage material, which clearly warrants further advancement to clinical trials. Similar approaches involving multiple parenchymal injections have been effective in correcting CNS disease in other LSD models, including Niemann Pick type A mice, 14 Batten disease mice, 17 Mucopolysaccharidosis I or IIIb dogs 39 and α-mannosidosis cats. 15 Therapeutic Hex was effective against its native substrates as evidenced by reduction of sialic acid concentration in all samples and near normalization of GM2 and GA2 concentrations in brain samples. However, GM2 and GA2 are absent or found in only trace amounts in normal cats that are ⩾ 5 months old, so storage in AAV-treated SD cats was not completely cleared despite several fold normal Hex activity. Similarly, in SD mice 18 and GM1 gangliosidosis mice, 40 a therapeutic level of enzyme restoration resulted in greatly diminished, but not fully normalized ganglioside storage in some areas. As hypothesized in the mouse studies, residual biochemical storage in AAV-treated SD cats could be due to uneven therapeutic enzyme distribution within the sample with supranormal Hex activity in some cells skewing measurements of total activity. 18, 40 This scenario is particularly likely in the CI of two of three treated SD cats, which had intense Hex staining in the dorsal funiculus but patchy activity in gray matter, leading to the highest residual ganglioside storage of all samples tested (Supplementary Figure S1 ). The cat with superior CI Hex distribution (7-770, Figure 1c ) also had the lowest GM2 storage in the CI (Figure 4e ). The CI was similarly more resistant than other samples to clearance of storage material in GM1 gangliosidosis cats treated by intracranial gene therapy 24 and in Mucopolysaccharidosis I dogs treated by intravenous enzyme replacement therapy. 41 Mice with a similar LSD (Mucopolysaccharidosis IIIA) showed incomplete clearance of glycosaminoglycans in the brain at 4 months, but glycosaminoglycan content was normalized at 10-12 months. 13 Therefore, a sustained period of enzyme expression may be necessary to completely clear storage material.
In LSDs, elevation of non-deficient lysosomal enzyme activity may be due to impaired degradation and turnover of acid hydrolases or increased synthesis of acid hydrolases in storagedistended cells as lysosomal hydrolases are a target of the transcription factor TFEB, which translocates to the nucleus under conditions of lysosomal stress. 42 Normalization of α-mannosidase throughout the brain of AAV-treated SD cats correlated with the restoration of Hex activity and reduction of ganglioside storage. In accordance with the higher residual ganglioside storage in the CI versus the brain of AAV-treated SD cats, there was significant . The scale is based on gait defects, which ultimately define humane endpoint, with initial deficits at the age of 2.1 months. However, disease onset begins at the age of 1.3 months with subtle tremors of the head/tail that progress to overt wholebody tremors at the age of 2.4 months. (b) Shown are clinical rating scores for each individual AAV-treated SD cat and a composite for untreated SD cats (SD no tx, n = 14). Filled symbols denote the absence of tremors, open symbols denote the presence of subtle tremors and gray symbols denote the presence of overt whole-body tremors, which were absent in all AAV-treated cats. AAV-treated cats are shown by squares (7-770), triangles (7-774) or diamonds , and the composite of untreated SD cats is shown by circles.
reduction but not normalization of spinal cord α-mannosidase activity, likely due to uneven Hex distribution as already discussed.
Feline SD results from a mutation at the carboxyl terminus of the Hex beta subunit, which is 98.5% homologous to the wild-type protein. 23 Thus, immune responses to the therapeutic beta subunit are unlikely. Humoral immunity to the vector itself was clearly documented, though serum antibody titers to the AAVrh8 vector varied considerably between subjects at 6 and 16 weeks after injection. Importantly, Hex distribution was widespread and activity was above normal despite a substantial serum antibody response to the vector in two of three cats. It is unknown why 11-762 had a lower antibody response to the vector, but, as in humans, immune responses to a particular antigen can vary. Although 11-762 maintained a slightly higher clinical rating score compared with the other two cats at the study endpoint, longterm studies are needed to determine if there is a correlation between antibody level and clinical outcome. Although asymmetrical distribution of antibodies across the blood-brain barrier may have played a role, 13 it is also likely that very low levels of preexisting antibodies to the novel AAVrh8 capsid allowed the vector to transduce cells effectively before a humoral immune response was generated. In a study in non-human primates, the presence of pre-existing serum antibodies blocked subsequent CNS transduction following AAV administration. 43 In other studies, the presence of pre-existing serum antibody titers resulted in a small attenuation of CNS vector transduction in dogs 13 and non-human primates. 44 However, the transduction of peripheral tissues was blocked. 13 Therefore, the presence of pre-existing antibodies could have implications for SD cats if vector re-administration for treatment of peripheral tissues ever becomes necessary.
Hex activity reached supranormal levels similar to those previously reported in clinically normal AAV-treated heterozygote cats. 20 In transgenic mice and AAV-treated heterozygote cats, massive overexpression of lysosomal enzyme was clinically benign and did not affect life span even though very high enzyme levels were present in lysosomes. 20, 45 However, toxicity due to overexpression of green fluorescent protein and Tau in the substantia niagra of mice has been reported. 46 Therefore, toxicity due to overexpression may be protein-, cell-type-and/or species-dependent, so caution must be applied when translating approaches from cats to other species, including humans.
Other caveats of the current study include the low number of animals, necessitated by our commitment to use the fewest animals possible to attain statistically significant results, especially when sentience is relatively high as in cats. However, the fact that statistical significance was achieved for enzyme restoration and clearance of storage with only three treated animals serves to underscore the power of our approach. For similar concerns about animal usage, we ended the study at a predetermined time point to make certain that biochemical results supported long-term studies in larger numbers of cats, which are underway currently. Finally, though results from injection of the thalamus and DCN are outstanding in the current report, intracranial targets are always a risk in humans, especially in the posterior fossa where severe hemorrhage is not uncommon.
Despite the limitations mentioned above, global correction of a lysosomal enzyme deficiency throughout the brain and spinal cord is unusual, especially in large animals. Improved efficacy of gene therapy for numerous diseases is expected to result from the continual development and testing of novel capsid proteins, such as AAVrh8. Though reported only recently, 47 AAVrh8 performed at least as effectively as other more common capsids for CNS gene delivery after intravenous injection 48 and was as efficacious as AAV1 for long-term therapeutic benefit in feline GM1 gangliosidosis. 24 In the current study, AAVrh8 provided pronounced therapeutic enzyme distribution and clinical benefit in all treated SD cats. At the study endpoint, subjects displayed only mild disease symptoms and were otherwise active and in excellent physical health. Successful translation of this treatment approach from mice to cats, which have a 450 times larger brain size, is predictive of effective scale-up to humans. The ability to achieve near-global CNS distribution of therapeutic enzyme from only four injection sites in a second feline LSD model 24 is encouraging for the further development of treatments for these devastating neurological diseases.
MATERIALS AND METHODS
AAV vector design and preparation AAV vectors were produced as previously described by triple transfection of 293T cells with vector plasmid (derived from the plasmid pAAV-CBA-MGB-W by replacing MGB with cDNA for feline HEXA or feline HEXB), 20 a mini adenovirus helper plasmid pFΔ6 and AAVrh8 helper plasmid pAR8. 49 The inverted terminal repeats in the vectors are derived from AAV2. Transgene expression is controlled by a hybrid CMV enhancer/chicken β-actin promoter. All vectors carry the woodchuck hepatitis virus posttranscriptional regulatory element.
Surgery and treatment groups
The feline SD breeding colony is maintained at Auburn University, whose institutional animal care and use committee approved the research described herein. Affected SD cats were treated between 1.0 and 1.3 months of age, prior to disease onset (1.3 ± 0.2 months) as determined by the clinical scale in Figure 7a . Anesthesia was induced with ketamine (10 mg kg − 1 ) and dexmedetomidine (0.04 mg kg − 1 ) through an intravenous catheter and maintained using isoflurane (0.5-1.5%) in oxygen delivered through an endotracheal tube. Cats were positioned sternally for intracranial injection using a Horsley-Clark stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA) and injected with vector bilaterally in the thalamus and deep cerebellar nuclei. Craniotomy sites were made with a 20 gauge needle at the following distances (in cm) from bony landmarks on the skull: thalamus (relative to bregma), anterior-posterior (AP) − 0.65, mediolateral (ML) ± 0.4, dorsoventral (DV) − 1.6 (from meninges); DCN (relative to lambda), AP 0.0, ML ± 0.4, DV − 1.25 (from meninges). Vector was delivered using a Hamilton syringe (Harvard Apparatus, Holliston, MA, USA) with a non-coring needle (22 to 25 G). A total of 70 μl was injected into each thalamus in 10-20 μl boluses, and a total of 24 μl was injected into each deep cerebellar nuclei in a 10 and 14 μl bolus. Injection rate was 2 μl min − 1 , and the needle was raised 0.15 cm between boluses for a total of four (thalamus) or two (deep cerebellar nuclei) injection depths. Animals were given AAVrh8-fHEXA+AAVrh8-fHEXB in a 1:1 ratio in a total injected dose of 4.4 × 10 12 vector genomes. AAV-treated cats (n = 3) were killed 16 weeks after injection for biochemical analysis of therapeutic effect. Controls were age-matched untreated normal cats (homozygous for the wild-type allele, n = 4 for all analyses) and untreated SD cats (n = 5 for enzyme analysis, n = 3 for isozyme analysis, n = 6 for storage analysis and n = 14 for clinical analysis).
Tissue preparation
Brains were divided into coronal blocks of 0.6 cm from the frontal pole through the cerebellum (Figure 1a ). Coronal blocks from the right hemisphere were frozen in optimum cutting temperature medium and used for analysis of Hex distribution by naphthol staining, Hex-specific activity by 4-methylumbelliferone (4MU) enzyme assays and AAV vector distribution by SYBR Green quantitative PCR. Coronal blocks from the left hemisphere were halved to 0.3 cm and stored at − 80°C for analysis of storage material by HPTLC or fixed in 10% formalin for routine hematoxylin and eosin staining (all blocks from cat 7-770 and cerebellar block H from cats 11-762 and 7-774).
Diethylaminoethyl cellulose anion exchange chromatography
Several frozen sections (50 μm) were cut from the coronal block containing the thalamus injection site (block D or E in Figure 1a ). Frozen brain tissue was extracted and analyzed as previously described. 20 Determination of lysosomal enzyme activity and distribution For brain and spinal cord tissue extraction, several frozen sections (50 μm) were cut from each coronal block (Figure 1a ). For sciatic nerve and pituitary tissue extraction, a sample was taken from the tissue stored at − 80°C. Tissue was homogenized manually in 50 mM citrate phosphate buffer, pH 4.4 (50 mM citric acid, 50 mM Na 2 HPO 4 , 10 mM NaCl) containing 0.1% TritonX and 0.05% bovine serum albumin, followed by two freeze-thaw cycles and centrifugation at 15 700 g for 5 min at 4°C. CSF samples were analyzed directly from − 80°C. MUGS, MUG and α-mannosidase assays were performed as previously described using synthetic 4-methylumbelliferone (4MU) fluorogenic substrates. 24 Hex activity in 8 mm punch biopsy samples (also used for HPTLC) was measured as previously described. 33 Lysosomal enzyme-specific activity was expressed as nmol 4 MU mg − 1 h − 1 .
To qualitatively assess the distribution of Hex activity, frozen sections at 40 μM were thawed and fixed for 15 min in the presence of 0.1% glutaraldehyde and 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.25. Sections were washed in phosphate-buffered saline and then in citrate phosphate buffer (50 mM Na 2 HPO 4 .7H 2 O, 50 mM citric acid monohydrate), pH 4.5. Tissue sections were then stained with AS-BI-N-acetyl-B-Dglucosaminide (naphthol) as previously described. 50 Lipid extraction and sialic acid quantification Punch biopsy samples of 8 mm were homogenized in water and lyophilized overnight. Lipid isolation and purification have been detailed previously. 20, 27 Total ganglioside content was quantified before and after desalting using a resorcinol assay.
High-performance thin layer chromatography
All lipids were analyzed qualitatively by HPTLC as detailed previously. 20, 27 Each lane was spotted with 1.5 μg sialic acid for acidic gangliosides and 200 μg of dry weight for GA2.
Quantification of individual lipids
The percent distribution and density of individual bands was determined as previously described. 33 Total brain ganglioside distribution was normalized to 100% and the percentage distribution values were used to calculate sialic acid concentration of GM2 (microgram per 100 mg dry weight). Density values of GA2 were fit to a standard curve and used to calculate individual concentrations.
Serum antibody analysis
Serum antibody titers were determined as previously described. 20 Quantitative PCR for vector genomes Vector copy number was quantified as previously described 24 by quantitative PCR using SYBR Green-based reactions (Applied Biosystems, Warrington, UK) with primers specific for woodchuck hepatitis virus posttranscriptional regulatory element in the vector (forward 5′-AGTTG TGGCCCGTTGTCA-3′; reverse 5′-GAGGGGGAAAGCGAAAGT-3′). Concentration of genomic DNA samples was 20 ng for spinal cord, 50 ng for brain and 25 ng for pituitary and sciatic nerve. Background amplification was determined on DNA from untreated normal and untreated SD cats. The assay limit of detection above background was 20 AAV copies per reaction.
Statistical analysis
Statistics were performed in SAS 9.2 software (SAS Institute Inc., Cary, NC, USA). The Wilcoxon rank sum test was used for pairwise comparisons of lysosomal enzyme activity, ganglioside concentrations and Hex isozyme ratios. Three pairwise comparisons were made: (i) AAV-treated versus normal, (ii) AAV-treated versus untreated and (iii) normal versus untreated. One-sided testing is reported for directional significance (i.e., significantly higher or lower), which may otherwise not be realized using two-sided testing because of low animal numbers when using a feline model. P ⩽ 0.05 was considered significant. Data are expressed as mean ± s.d throughout the text and figures.
